Expert view: GenScript’s unique four-tier platform for successful synthesis of challenging neoantigen peptides for precision medicine

Given this drastic statistic, researchers are developing personalised immunotherapies that, as opposed to one-size-fits-all approaches, train a patient’s immune system to attack and kill their own cancerous tissue based on individualised tumour biomarkers known as neoantigens. Unlike common tumour-associated antigens, neoantigens are only expressed in cancer and are therefore highly immunogenic.